ClinicalTrials.gg
RecruitingNCT07173829BORDEAUX-GLIOUpdated Aug 7, 2026

A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression

An observational study in Glioblastoma, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by University Hospital, Bordeaux · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Glioblastoma with a site in France — 35 open to participants now, 51 under way, 9 of them phase 3. Glioblastoma · France.

Planned enrollment
13th of 18
45 · median 114
Started
2025
with 7 others
Observational
18 of 150
7 open now
Primary completion
2031-10
later than 48 of 50 live
Registered
125th of 150
by date

Among the 150 studies in Glioblastoma with a site in France, this one is the 13th largest by planned enrollment of the 18 observational ones that give a count, is one of 8 that started in 2025, is one of 18 observational ones, reaches primary completion later than 48 of the 50 other live ones, and was the 125th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

35 of the 150 studies in Glioblastoma with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Glioblastoma with a site in France, or all of them as a file.
02

Study summary

BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.

Read the detailed description

Glioblastoma is the most common and aggressive primary brain tumor in adults, whose relapse is almost systematic despite surgery, radiation therapy and temozolomide (STUPP protocol). Several clinical trials evaluating targeted therapy and immune checkpoint inhibitors have led to disappointed results. There is an unmet need to better understand the molecular and immune mechanisms underlying the invasion and progression of these tumors, in order to identify new therapeutic targets. The Bordeaux University Hospital is a leading French treatment center for glioblastoma, providing a large number of biological samples that can be analyzed at the molecular, immune and metabolic levels by specialized local teams.

Tumor tissue will be collected during patient surgery from primitive or recurrent glioblastoma, as well as blood samples, to perform transcriptomic and metabolomic analysis, including spatial transcriptomic and metabolomic, ex vivo generation of γδT lymphocytes and patient-derived xenografts.

A secondary objective is to develop, in preclinical models, innovative drugs with radiosensitizing effect and a γδT cell immunotherapy active against glioblastoma.

03

Conditions studied

  • Glioblastoma

Browse trials for

Keywords

  • Glioblastoma progression
  • Glioblastoma recurrence
  • Metabolism
  • Lactate
  • Metabolomic
  • Transcriptomic
  • Radiation therapy
  • Radiosensitizer
  • Immunotherapy
  • γδ T lymphocytes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
  • Planned surgical tumor resection,
  • No objection to participate in research
  • Signed genetic consent

Exclusion criteria

Exclusion Criteria:

  • Patients under guardianship, curatorship or protective supervision
  • Taking
  • Pregnant or breast-feeding women
  • Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Recruited patient

    Glioblastoma patient with indication for neurosurgery

    Other: samples

Interventions

  • Othersamples

    A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.

06

What researchers measure

Primary outcomes

  1. Molecular mechanism

    Description of the molecular mechanism involved in the progression and recurrence of glioblastoma

    Time frame: at inclusion (T0)

  2. Metabolic mechanism

    Description of the metabolic mechanism involved in the progression and recurrence of glioblastoma.

    Time frame: at inclusion (T0)

  3. Immune mechanism

    Description of the immune mechanism involved in the progression and recurrence of glioblastoma

    Time frame: at inclusion (T0)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2031, 72 months after the start.

Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 72 months is above that.

Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2023
First posted
Sep 15, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Oct 2031
CompletionEst.
Oct 2031
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07173829
Collaborators
University of Bordeaux
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Oct 22, 2025
Primary completion
Oct 2031 (estimated)
Completion
Oct 2031 (estimated)
Last update
Aug 7, 2026

Study contacts

Julien ENGELHARDT, Dr
Contact
julien.engelhardt@chu-bordeaux.fr
05 56 79 55 77 ext. +33
Olivier BRANCHARD
Contact
olivier.branchard@chu-bordeaux.fr
05 57 82 06 97 ext. +33
Julien ENGELHARDT, Dr
principal investigator · University Hospital, Bordeaux
Mathieu LARROQUETTE, Dr
study chair · University Hospital, Bordeaux
Guillaume CHOTARD, Dr
study chair · University Hospital, Bordeaux
Lionel COUZI, Pr
study chair · Bordeaux university Hospital, Bordeaux University
Andreas BIKFALVI, Pr
study chair · University of Bordeaux
Charles DUPIN, Dr
study chair · University Hospital, Bordeaux
Véronique VENDRELY, Pr
study chair · Bordeaux university Hospital, Bordeaux University
Julie DECHANET-MERVILLE, Dr
study chair · University of Bordeaux
Thomas DAUBON, Dr
study chair · University of Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion